Alzheimer's News Today Home | Alzheimer's News Today
WEBSep 23, 2024 — Need to know. Becoming educated and informed about Alzheimer’s is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes. Get informed.
ALZ-801 for 2 years seen to sustain cognition in early Alzheimer’s
WEBSep 22, 2023 — Treatment for two years with oral ALZ-801 (valiltramiprosate) sustained cognition and lowered levels of disease-related biomarkers in people with early Alzheimer’s disease carrying one or two copies of the disease-linked APOE4 genetic variant.
News Archives - Alzheimer's News Today
WEBOral AMX0035 found to improve core Alzheimer’s-related biomarkers. Amylyx Pharmaceuticals‘ investigational oral therapy AMX0035 reduces the levels of several biomarkers associated with Alzheimer’s disease, according to an analysis of data from the PEGASUS trial.
About Us - Alzheimer's News Today
WEBAlzheimer’s News Today is a digital platform intended to provide the Alzheimer’s disease community with the most recent news and information on the disease, as well as first-hand community perspectives from our patient and caregiver columnists.
Topline results of Phase 3 studies of simufilam for Alzheimer's...
WEBFeb 8, 2024 — Two Phase 3 clinical trials are testing the effectiveness of simufilam, an experimental oral therapy that’s designed to improve cognition in people with Alzheimer’s disease. Top-line results from the RETHINK-ALZ trial (NCT04994483) are expected by the end of this year, according to simufilam’s developer Cassava Sciences.
AAN 2023: ALZ-801 for Alzheimer's helps improve cognition in trial...
WEBApr 28, 2023 — One year of treatment with ALZ-801 (valiltramiprosate) was found in a Phase 2 trial to improve cognition and lower the levels of disease biomarkers among people with early Alzheimer’s with one or two copies of the apolipoprotein E4 (APOE4) disease-associated genetic variant.
Lecanemab Slows Dementia of Early Alzheimer’s in Phase 3 Trial
WEBOct 4, 2022 — Treatment with lecanemab (BAN2401), an experimental amyloid-targeting antibody, significantly slowed the progression of dementia symptoms among people with early Alzheimer’s disease in the Phase 3 Clarity …
Simufilam aids cognition in 47% of Alzheimer's patients in Phase 2...
WEBMar 14, 2023 — Nearly half of some 200 mild-to-moderate Alzheimer’s patients treated with oral simufilam for one year showed gains in cognitive tests.
Subscribe – Alzheimer's News Today
WEBPublishing the web’s most comprehensive platform for Alzheimer’s News, columns, patient perspectives and resources requires a significant investment of resources each month for our talented and growing staff of PhD researchers, veteran journalists, talented social media team, and patient columnists.
Aduhelm Approval Greeted With Joy, Concern in Alzheimer’s …
WEBJun 17, 2021 — Aduhelm, by Biogen and Eisai, is the first disease-modifying therapy for Alzheimer’s, meaning it is capable of slowing the progression of the disease, and not just its symptoms. The treatment was under the FDA’s accelerated approval program, which allows earlier access to therapies even if there is uncertainty about the clinical benefit.